Pancreatic neuroendocrine tumors (PanNET) comprise two molecular subtypes, relatively benign islet tumors (IT) and invasive, metastasis-like primary (MLP) tumors. Until now, the origin of aggressive MLP tumors has been obscure. Herein, using multi-omics approaches, we revealed that MLP tumors arise from IT via dedifferentiation following a reverse trajectory along the developmental pathway of islet β cells, which results in the acquisition of a progenitor-like molecular phenotype. Functionally, the miR-181cd cluster induces the IT-to-MLP transition by suppressing expression of the Meis2 transcription factor, leading to upregulation of a developmental transcription factor, Hmgb3. Notably, the IT-to-MLP transition constitutes a distinct step ...
Pancreatic cancer is currently the third leading cause of cancer death and projected to be the secon...
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by a hi...
Pancreatic cancer is the 4th leading cause of cancer-related death in Canada. A major reason for the...
Pancreatic neuroendocrine tumors (PanNET) comprise two molecular subtypes, relatively benign islet t...
Pancreatic Neuroendocrine Tumors (PanNETs) comprise two molecular subtypes, relatively benign islet ...
Seeking to assess the representation and instructive value of an engineered mouse model of pancreati...
Pancreatic cancer, a highly aggressive tumour type with uniformly poor prognosis, exemplifies the cl...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a low survival rate. This is no...
OBJECTIVE: The initial steps of pancreatic regeneration versus carcinogenesis are insufficiently und...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. High mortality rate is a co...
Pancreatic cancer is the fourth leading cause of cancer related death in the United States, with pan...
Pancreatic neuroendocrine tumors (PanNETs) are a relatively rare but clinically challenging tumor ty...
Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) are non-invasi...
Pancreatic adenocarcinoma displays a variety of molecular changes that evolve exponentially with ti...
Despite recent advances in cancer treatment, resistance to therapy and metastatic progression remain...
Pancreatic cancer is currently the third leading cause of cancer death and projected to be the secon...
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by a hi...
Pancreatic cancer is the 4th leading cause of cancer-related death in Canada. A major reason for the...
Pancreatic neuroendocrine tumors (PanNET) comprise two molecular subtypes, relatively benign islet t...
Pancreatic Neuroendocrine Tumors (PanNETs) comprise two molecular subtypes, relatively benign islet ...
Seeking to assess the representation and instructive value of an engineered mouse model of pancreati...
Pancreatic cancer, a highly aggressive tumour type with uniformly poor prognosis, exemplifies the cl...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a low survival rate. This is no...
OBJECTIVE: The initial steps of pancreatic regeneration versus carcinogenesis are insufficiently und...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. High mortality rate is a co...
Pancreatic cancer is the fourth leading cause of cancer related death in the United States, with pan...
Pancreatic neuroendocrine tumors (PanNETs) are a relatively rare but clinically challenging tumor ty...
Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) are non-invasi...
Pancreatic adenocarcinoma displays a variety of molecular changes that evolve exponentially with ti...
Despite recent advances in cancer treatment, resistance to therapy and metastatic progression remain...
Pancreatic cancer is currently the third leading cause of cancer death and projected to be the secon...
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by a hi...
Pancreatic cancer is the 4th leading cause of cancer-related death in Canada. A major reason for the...